Cargando…
Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al
Autores principales: | Skobieranda, Franck, Candler, Shawn, Macfadden, Wayne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189932/ https://www.ncbi.nlm.nih.gov/pubmed/35695180 http://dx.doi.org/10.1093/sleep/zsab292 |
Ejemplares similares
-
Response to: Once-nightly sodium oxybate (FT218) in the treatment of
narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et
al
por: Kushida, Clete A, et al.
Publicado: (2022) -
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021) -
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023) -
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
por: Roth, Thomas, et al.
Publicado: (2022) -
Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary
por: Rosenberg, Russell, et al.
Publicado: (2023)